These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

973 related articles for article (PubMed ID: 33984285)

  • 1. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans.
    Vanshylla K; Di Cristanziano V; Kleipass F; Dewald F; Schommers P; Gieselmann L; Gruell H; Schlotz M; Ercanoglu MS; Stumpf R; Mayer P; Zehner M; Heger E; Johannis W; Horn C; Suárez I; Jung N; Salomon S; Eberhardt KA; Gathof B; Fätkenheuer G; Pfeifer N; Eggeling R; Augustin M; Lehmann C; Klein F
    Cell Host Microbe; 2021 Jun; 29(6):917-929.e4. PubMed ID: 33984285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
    Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
    Front Immunol; 2022; 13():829665. PubMed ID: 35154152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.
    Dispinseri S; Secchi M; Pirillo MF; Tolazzi M; Borghi M; Brigatti C; De Angelis ML; Baratella M; Bazzigaluppi E; Venturi G; Sironi F; Canitano A; Marzinotto I; Tresoldi C; Ciceri F; Piemonti L; Negri D; Cara A; Lampasona V; Scarlatti G
    Nat Commun; 2021 May; 12(1):2670. PubMed ID: 33976165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
    Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
    Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.
    Yang Y; Yang M; Peng Y; Liang Y; Wei J; Xing L; Guo L; Li X; Li J; Wang J; Li M; Xu Z; Zhang M; Wang F; Shi Y; Yuan J; Liu Y
    Nat Microbiol; 2022 Mar; 7(3):423-433. PubMed ID: 35132197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.
    Glöckner S; Hornung F; Baier M; Weis S; Pletz MW; Deinhardt-Emmer S; Löffler B; The CoNAN Study Group
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals.
    Markmann AJ; Giallourou N; Bhowmik DR; Hou YJ; Lerner A; Martinez DR; Premkumar L; Root H; van Duin D; Napravnik S; Graham SD; Guerra Q; Raut R; Petropoulos CJ; Wrin T; Cornaby C; Schmitz J; Kuruc J; Weiss S; Park Y; Baric R; de Silva AM; Margolis DM; Bartelt LA
    mSphere; 2021 Aug; 6(4):e0027521. PubMed ID: 34431693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections.
    Lei Q; Li Y; Hou HY; Wang F; Ouyang ZQ; Zhang Y; Lai DY; Banga Ndzouboukou JL; Xu ZW; Zhang B; Chen H; Xue JB; Lin XS; Zheng YX; Yao ZJ; Wang XN; Yu CZ; Jiang HW; Zhang HN; Qi H; Guo SJ; Huang SH; Sun ZY; Tao SC; Fan XL
    Allergy; 2021 Feb; 76(2):551-561. PubMed ID: 33040337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 3 SARS-CoV-2 IgG Antibody Assays and Correlation with Neutralizing Antibodies.
    Rychert J; Couturier MR; Elgort M; Lozier BK; La'ulu S; Genzen JR; Straseski JA; Delgado JC; Slev PR
    J Appl Lab Med; 2021 Apr; 6(3):614-624. PubMed ID: 33064790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
    Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
    mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiplex assessment of SARS-CoV-2 antibodies improves assay sensitivity and correlation with neutralizing antibodies.
    Cook N; Xu L; Hegazy S; Wheeler BJ; Anderson AR; Critelli N; Yost M; McElroy AK; Shurin MR; Wheeler SE
    Clin Biochem; 2021 Nov; 97():54-61. PubMed ID: 34453893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals.
    Butler SE; Crowley AR; Natarajan H; Xu S; Weiner JA; Bobak CA; Mattox DE; Lee J; Wieland-Alter W; Connor RI; Wright PF; Ackerman ME
    Front Immunol; 2020; 11():618685. PubMed ID: 33584712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up.
    Matusali G; Sberna G; Meschi S; Gramigna G; Colavita F; Lapa D; Francalancia M; Bettini A; Capobianchi MR; Puro V; Castilletti C; Vaia F; Bordi L
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
    Moriyama S; Adachi Y; Sato T; Tonouchi K; Sun L; Fukushi S; Yamada S; Kinoshita H; Nojima K; Kanno T; Tobiume M; Ishijima K; Kuroda Y; Park ES; Onodera T; Matsumura T; Takano T; Terahara K; Isogawa M; Nishiyama A; Kawana-Tachikawa A; Shinkai M; Tachikawa N; Nakamura S; Okai T; Okuma K; Matano T; Fujimoto T; Maeda K; Ohnishi M; Wakita T; Suzuki T; Takahashi Y
    Immunity; 2021 Aug; 54(8):1841-1852.e4. PubMed ID: 34246326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection.
    Vangeti S; Periasamy S; Sun P; Balinsky CA; Mahajan AS; Kuzmina NA; Soares-Schanoski A; Cooper E; Beckett C; Marayag J; Marrone A; Nunez E; Ge Y; Porter CK; Goforth CW; Lizewski SE; Lizewski R; Jani V; Sugiharto VA; Schilling M; Yu XB; Marjanovic N; George MC; Bukreyev A; Sealfon SC; Letizia AG; Ramos I
    Microbiol Spectr; 2022 Dec; 10(6):e0183722. PubMed ID: 36374040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition.
    Maciola AK; La Raja M; Pacenti M; Salata C; De Silvestro G; Rosato A; Pasqual G
    Front Immunol; 2022; 13():830710. PubMed ID: 35173741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.